Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy - Wikidata - awgldk - TriplyDB

Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

http://www.wikidata.org/entity/Q35022139

about

Cytoplasmic targeting of the proto-oncogene SET promotes cell spreading and migration Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia Endogenous inhibitor proteins that connect Ser/Thr kinases and phosphatases in cell signaling.The Rac1 hypervariable region in targeting and signaling: a tail of many stories The Basic Biology of PP2A in Hematologic Cells and Malignancies Signaling and stress: The redox landscape in NOS2 biology Protein Ser/Thr phosphatases--the ugly ducklings of cell signalling.Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein Subcellular proteomics reveals a role for nucleo-cytoplasmic trafficking at the DNA replication origin activation checkpoint Cracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.Functional modulation of the metastatic suppressor Nm23-H1 by oncogenic viruses Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia Viewing serine/threonine protein phosphatases through the eyes of drug designers Identification of miR-145 targets through an integrated omics analysis.SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.The N-terminal Set-β Protein Isoform Induces Neuronal Death Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.Human apolipoprotein E genotypes differentially modify house dust mite-induced airway disease in mice Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.Protein phosphatase 2A: a target for anticancer therapy.PP2A-Mediated Anticancer Therapy.OP449 inhibits breast cancer growth without adverse metabolic effects.All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.SET/I2PP2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line.Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015).Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation.

P2860

Q24305121-2222C1FD-FB74-4CA5-AF8D-C0C42E70719A Q26752430-033CDEA4-AA5B-4A75-9F54-F5C6608844AA Q26849244-6C092417-0940-4EA8-83D3-9381066EBD6A Q26864271-497FA0C0-0701-4962-BC39-26668F3B91C0 Q28088697-F890ABFF-12C7-4F89-9295-09E7E61372B9 Q28833738-9D12B31C-6D01-4BD3-97E5-49F97E56F396 Q30455386-65C9CABC-2106-4D98-AD23-EEC4910F2B47 Q33835127-E258CA6E-C3C5-4887-AC21-595077150A79 Q33977247-3440FEFB-6777-48FD-9F92-E58BE1D5F6B2 Q34007879-3C274E76-5155-4B89-8A9F-8A8F50399B6A Q34555685-2E4FDCDF-ACDD-4EA4-895F-8F989EE28061 Q34667732-7DC0A5D8-69CF-47A1-9F18-826F3A119CD9 Q34730329-13481401-E32C-48E5-A786-A85B9EB99597 Q34901718-A8FBFD51-8413-43A7-BAD5-0ABD060512BE Q35037262-C345C70C-97A3-4965-BDC7-BAC5DAA21222 Q35146774-C5B4554F-02B4-4BBB-957F-0A36B6DEC069 Q35155627-93C2F1FB-426F-4F13-B8D4-82D9243F24D6 Q35483640-1BA171CD-B6F2-45CA-9B91-78B7A98BB531 Q35552005-D0D3BD04-F9E5-4984-B933-AE7CFF371D60 Q35828517-6485BDCD-D2C6-417C-AC14-89F81E243DBF Q35861000-20A834CF-3D02-441E-9ED5-45FFAB9EA694 Q35944719-2438E2A6-7AFE-4AAB-A305-EF0D6E983233 Q35950145-619A337F-E3A4-4FCC-B778-77C07E0C596F Q36020877-1D63E7FF-F8C2-4E5E-88DA-E2A91F5F14EF Q36050039-9562AF6F-B24E-4E3C-8C36-47F75B5BDD66 Q36275673-CBCD1DAB-A71B-47CB-8C7D-AB93CF93D2D3 Q36729492-2F1C8508-AB8A-4A3C-A199-007A94A42B89 Q37607196-69A2D0C6-73A7-4659-9493-E5A6C5BC7B38 Q37707099-CF04CEDE-9F47-4A23-8A2E-2BF09893D84D Q37708933-828A4F9D-BBBC-4B03-88DB-D9A19CBE4031 Q38103646-2E58CEDE-81A4-4B40-B10E-9C359B30DB71 Q38168831-E6C04400-1598-4486-B2C2-B9DFDDCFDFA4 Q38613399-CD5A9F20-D119-4020-A714-794F985F517A Q38617799-2F99E337-BFD4-4872-9AE8-E812B59BCC77 Q38678579-E452EF87-D4D7-428E-A69D-A7F111BCC97A Q38699543-B5EB680A-3F4B-4F13-A286-BD3D1874E974 Q38725557-F12A1A3A-6E39-4A91-854E-002210E85854 Q38904928-DC085B11-F646-40B9-A4A8-1032EB8136AB Q39097201-C9ECED9B-B9E9-4956-9BF0-7D21318E3AF8 Q39333626-F95492C3-7E99-4C22-B9B3-6255C664B4A0

P2860

Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

http://www.wikidata.org/entity/Q35022139

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy

@ast

Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy

@en

type

label

Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy

@ast

Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy

@en

prefLabel

Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy

@ast

Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy

@en

P1433

Q35022139-7E36FE46-5D04-4350-92D6-97455D8DC066

P1476

Q35022139-19D424B9-7129-45EC-996A-F48B6B376F72

P2093

Q35022139-6DD3B425-CEEE-4E7F-9CB7-0F0B561206AB

Q35022139-B699CC4F-946A-4C9E-BB06-45D63A02D469

Q35022139-C4204501-540C-4407-B073-5852F058D9EE

Q35022139-CF369FF2-D7C5-4DD4-8D81-A6A136C7361F

Q35022139-F29E10F4-C935-4E10-8571-A316BD174EE7

P2860

Q35022139-046C096A-E31E-4207-A3E8-A06E6A06FAC0

Q35022139-0F50148F-4F30-424F-9A41-F1B91CC93073

Q35022139-13F51D34-1B32-4B1C-A86C-A37CE6BDE4CB

Q35022139-142FA268-0C53-4BD2-A85F-43E0DEF1EF3B

Q35022139-160D0065-1C5F-4A92-B39C-9B158513DB06

Q35022139-1663199D-8547-4BBF-A3DF-6BAC9B7A1F0C

Q35022139-187127C7-CFA1-4240-8288-3713F486710B

Q35022139-1A6D6C0B-4F10-4D20-AF9D-8EBFAF9914B8

Q35022139-32C2BC1B-0FDE-46C7-A126-F42A352BB51E

Q35022139-394E7B9D-82A9-4259-905A-F8FD11D20FF0

P2888

Q35022139-016613D0-2D7D-4982-813F-46A172649B5F

P304

Q35022139-60F49F36-3546-495B-8878-E9316E07DE2E

P31

Q35022139-C10432D6-E611-4A64-B9B1-BA200B5EFDF1

P356

Q35022139-3962E015-F0BC-4746-AC60-799FC02CE317

P407

Q35022139-34F5BC77-2A88-47EC-8E4F-F01BDEE857E8

P433

Q35022139-630587A3-CF5C-41DE-9B7D-733891CEF0BA

P478

Q35022139-18A9C6C2-B208-45F1-A31F-A10AFD21D2E3

P50

Q35022139-4DE97F9D-AEAF-4E58-8FEB-3AD269791EDF

P577

Q35022139-BC76F886-C3E2-4880-8A72-4385FA257481

P5875

Q35022139-19F508F3-993A-4F51-93BF-34B433AD7329

P698

Q35022139-01363C10-816E-4B82-8D64-E60D56E19E91

P932

Q35022139-29B5DFA8-1192-45FA-B135-56F4CF0263B8

P356

P1433

P1476

Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy

@en

P2093

C H Switzer

http://www.w3.org/2001/XMLSchema#string

D A Wink

http://www.w3.org/2001/XMLSchema#string

D J Christensen

http://www.w3.org/2001/XMLSchema#string

M P Vitek

http://www.w3.org/2001/XMLSchema#string

T M Vitek

http://www.w3.org/2001/XMLSchema#string

P2860

Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET

Constitutive induction of p-Erk1/2 accompanied by reduced activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen species during cellular senescence

The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A

CIP2A inhibits PP2A in human malignancies

Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene

Tumor metastasis suppressor nm23H1 regulates Rac1 GTPase by interaction with Tiam1

Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein

Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor

ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases

Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development

P2888

P304

2504-2513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2010.622

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Robert Y S Cheng

P577

2011-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49813968

http://www.w3.org/2001/XMLSchema#string

P698

21297667

http://www.w3.org/2001/XMLSchema#string

P932

3107340

http://www.w3.org/2001/XMLSchema#string